Collaboration with Tel Aviv University

Mar 20, 2022 | BALTIMORE –  Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University on a clinical proteomics project focusing on leveraging our Complete360 body fluid proteomics assays for clinical discoveries.

Tel Aviv University (TAU) (Hebrew: אוּנִיבֶרְסִיטַת תֵּל אָבִיב, Universitat Tel Aviv) is a public research university in Tel Aviv, Israel. With over 30,000 students, it is the largest university in the country. Located in northwest Tel Aviv, the university is the center of teaching and research of the city, comprising 9 faculties, 17 teaching hospitals, 18 performing arts centers, 27 schools, 106 departments, 340 research centers, and 400 laboratories. Besides being the largest university in Israel, Tel Aviv University is also the largest Jewish university in the world.

Dr. Weil’s research interests focus on The role of programmed cell death (PCD) in the developing nervous system and Neuronal differentiation of human embryonic and adult stem cells in Familial Dysautonomia (FD) and other neurodegenerative disceases

The collaboration beween Complete Omics Inc and Dr. Weil is focusing on very demanding body fluid proteomics assays which our unique patented Complete360 is designed to tackle.

Follow by Email